Kaul S, Gosmanova EO, Castriota F, Hitchens A, Candrilli S, Parikh R, Esterberg E, Ayodele O. Recent trends in hypoparathyroidism-related inpatient and emergency department admissions and costs in the United States. J Endocr Soc. 2023 Apr 18;7(5):bvad050. doi: 10.1210/jendso/bvad050.
Thomas A, Danon L, Christensen H, Northstone K, Smith D, Nixon E, Trickey A, Hemani G, Sauchelli S, Finn A, Timpson N, Brooks-Pollock E. Limits of lockdown: characterising essential contacts during physical distancing. Wellcome Open Res. 2021 May;6:116. doi: 10.12688/wellcomeopenres.16785.1
Ervin C, Joish VN, Castro C, DiBenedetti D, Evans E, Carroll A, Lapuerta P. Elevating the patient voice in type 1 diabetes clinical trials: a comparison of in-depth exit interviews and diabetes-specific questionnaires. Poster presented at the 2020 Endocrine Society Conference (ENDO2020) (Conference cancelled); March 2020. San Francisco, CA. [abstract] J Endocr Soc. 2020 May 8; 4(Suppl 1):MON-630. doi: 10.1210/jendso/bvaa046.1290
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Sorensen HT, Steffensen FH, Sabroe S, Rothman KJ, Gillman MW, Fischer P. Historical cohort study of in utero exposure to uterotonic drugs and cognitive function in young adult life. West J Med. 1999 Jan 1;170(5):260-2.